As healthcare policy evolves in the United States, chronic illness management is under significant strain. Budget cuts, restructuring, and changing insurance coverage have amplified challenges for patients managing long-term conditions. Amid these shifts, ivermectin has re-emerged as a topic of interest, particularly in discussions around alternative chronic illness care, Ivermectin care, affordability, and patient access.
Understanding the renewed focus on ivermectin requires a close look at chronic care policies, government programs, and patient-driven movements in 2025. This article explores trends, controversies, and potential implications for public health and healthcare innovation.
